What reMYND does

reMYND is a Belgian clinical-stage biotechnology company developing first-in-class oral small molecule therapeutics for neurodegenerative diseases, with primary programs in Alzheimer's disease and Huntington's disease. Founded in 2002 and headquartered at the Arenberg Science Park in Leuven (Bio Incubator 3 building), the company employs 11-50 staff and operates as an independent private entity with board representation from Belgian institutional investors including SFPIM, PMV, Korys, and KU Leuven Research & Development.

The company's core technology is a proprietary septin modulation platform, validated by a study published in Science in August 2024. The ReS19-T compound class targets septins — cytoskeletal proteins disrupted in neurodegeneration — acting as molecular glue to restore septin filament integrity and normalize calcium homeostasis in neurons, without affecting healthy cells. Lead clinical-stage assets include REM392 (a second-generation oral septin modulator for Alzheimer's disease, currently in Phase 1) and REM949 (an orally available small molecule with strong brain permeability targeting the neurotoxic effects of mutated huntingtin protein in Huntington's disease, positioned for CTA-enabling studies). A first-generation candidate, REM0046127 (REM127), demonstrated significant memory improvement and biomarker changes in a Phase 2a trial but was terminated due to off-target liver effects, informing the second-generation design. The company also maintains a discovery program targeting mitochondrial dysfunction in ALS.

Historically, reMYND operated a dual model combining proprietary drug development with CRO services that served Top 10 global pharmaceutical companies using its proprietary mouse models. In March 2025, the company divested the CRO business unit to InnoSer to focus exclusively on clinical drug development. As a pre-revenue biotech, reMYND expects future revenue from out-licensing or commercialization of its drug candidates through standard pharmaceutical distribution channels. The company is led by CEO Floor Stam, PhD, and CSO Gerard Griffioen, PhD, and engages the scientific community through publications, conference presentations (including CTAD), and AI partnerships such as its 2025 collaboration with Unlearn on digital twin technology for clinical signal interpretation.

Name

reMYND

Legal name

remynd NV

Website

https://www.remynd.com/

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

reMYND is a Belgian clinical-stage biotech developing first-in-class oral small molecule therapeutics for Alzheimer's and Huntington's disease using a proprietary septin modulation platform that restores calcium homeostasis in neurons.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Neurodegenerative therapeutics
• Alzheimer's drug development
• Huntington's disease treatment
• Small molecule drugs
• Clinical stage biotech

Headquarters

HQ city

Leuven

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Development Programs: Developing proprietary small molecule therapeutics for neurodegenerative diseases (Alzheimer's and Huntington's disease) through clinical stages. Revenue will be generated upon regulatory approval and commercialization of drug candidates.
2. CRO Services (Divested): Contract Research Organization services providing preclinical testing using proprietary mouse models for neurodegenerative diseases. This business unit was fully integrated into InnoSer in March 2025, ending reMYND's CRO operations.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

reMYND develops first-in-class oral small molecule drug candidates targeting neurodegenerative diseases, primarily Alzheimer's and Huntington's disease. The company's proprietary septin modulation platform restores calcium homeostasis in neurons by acting as a molecular glue to repair septin filament integrity. Lead candidates include REM392 (Alzheimer's, Phase 1), REM0046127/REM127 (Alzheimer's, Phase 2a completed), and REM949 (Huntington's, ready for CTA-enabling studies). Following the March 2025 divestiture of its CRO business to InnoSer, reMYND focuses exclusively on advancing these proprietary drug programs through clinical development.

Product overview

reMYND is a clinical-stage biotech company developing first-in-class oral treatments for neurodegenerative diseases, particularly Alzheimer's and Huntington's disease. The company's product portfolio centers on septin modulation technology—a novel mechanism targeting cytoskeletal proteins to restore calcium homeostasis in neurons. Lead programs include REM392 (second-generation Alzheimer's candidate in Phase 1), REM127 (first-generation Alzheimer's candidate completing Phase 2a), and REM949 (Huntington's disease candidate entering CTA-enabling studies). The company previously operated a CRO services business which was sold to InnoSer in March 2025, transitioning reMYND to a pure-play drug development organization. Research has been published in Science journal demonstrating the therapeutic potential of septin modulators.

Differentiator

Problem solved

Functional benefit

Products and services

• REM392 Second-generation oral small molecule septin modulator for Alzheimer's disease. Restores calcium balance in neurons by targeting septin filaments disrupted by pathological tau. Designed with improved safety profile and pharmacokinetics compared to first-generation candidate REM127. Currently in Phase 1 clinical trials (initiated May 2025).
• REM0046127 (REM127) First-generation small molecule drug candidate acting as molecular glue to restore septin filament integrity in neurons. Targeted mild-to-moderate Alzheimer's disease patients. Showed significant memory improvement and biomarker changes (p-tau181 reduction, EEG power increase, CSF dopamine increase) in Phase 2a trial. Program was terminated early due to off-target liver effects, leading to development of second-generation candidate REM392.
• REM949 Lead compound for reMYND's Huntington's disease program. Highly potent, orally available small molecule with excellent brain permeability and promising non-clinical safety and pharmacokinetic properties. Targets neurotoxic effects of mutated huntingtin protein. Ready to enter CTA-enabling studies.
• ReS19-T Compound Class Novel class of compounds identified through reMYND's Science publication that restore calcium homeostasis by targeting septins. Showed neuroprotective effects, reduced pathological protein accumulation, and improved memory function in multiple disease models of Alzheimer's. Forms the chemical foundation of reMYND's drug pipeline including REM392 and REM127.

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• InnoSercoreStrategic or Co-development Partner · 4 March 2025Strategic divestiture of reMYND's CRO business unit to InnoSer. The acquisition integrates reMYND's preclinical neuroscience models into InnoSer's neurology platform. This transition allows reMYND to focus exclusively on progressing its clinical drug programs while ensuring continuity of CRO services for global pharma and biotech clients.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Cassava Sciences: Clinical-stage US biotech developing oral small molecules (simufilam) for Alzheimer's disease with a novel mechanism targeting altered protein folding/scaffolding — closely comparable to reMYND in modality (oral small molecule), indication (AD), and disease-modifying ambition.
• Anavex Life Sciences: Clinical-stage biotech developing oral small molecules (blarcamesine) targeting sigma-1 receptor for Alzheimer's and other neurodegenerative diseases. Direct parallel to reMYND as an oral small-molecule CNS company pursuing disease modification.
• Denali Therapeutics: Clinical-stage biotech developing small molecules and biologics for neurodegenerative diseases (including Parkinson's and ALS) using novel biology-driven approaches. Comparable as a CNS-focused drug developer with multiple programs and strong institutional backing.
• AC Immune: Swiss clinical-stage biotech developing both small molecules and immunotherapies targeting misfolded proteins (tau, alpha-synuclein) in Alzheimer's and Parkinson's. Directly comparable to reMYND in targeting protein-misfolding biology in neurodegeneration.
• Prothena Corporation: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's, Alzheimer's and ATTR amyloidosis. Comparable as a protein-misfolding-focused CNS biotech with multiple clinical-stage programs.
• Prilenia Therapeutics: Clinical-stage biotech developing pridopidine, an oral small molecule for Huntington's disease and ALS. Direct comparable to reMYND on the Huntington's program specifically, sharing oral small-molecule modality and CNS indication.
• Wave Life Sciences: Clinical-stage biotech developing RNA-targeting therapies for Huntington's disease (and other CNS indications). Direct Huntington's competitor to reMYND's REM949, though differing in modality (antisense oligonucleotides vs. small molecule).
• uniQure: Clinical-stage gene therapy company developing AMT-130 for Huntington's disease. Comparable to reMYND's REM949 as another late-preclinical/early-clinical HD therapeutic, though uniQure uses AAV gene therapy rather than a small molecule.

Broad incumbents

• Biogen: Large biopharmaceutical company with leading Alzheimer's franchise (Leqembi, co-developed with Eisai) and a broader CNS/neurodegeneration pipeline. Comparable as the dominant commercial incumbent in AD that any disease-modifying small molecule like reMYND's would eventually compete against or partner with.
• Eisai: Global pharmaceutical company with a major Alzheimer's franchise (Leqembi, Kisunla) and a deep neurodegenerative-disease pipeline. Broad incumbent comparable to reMYND's commercial landscape and a likely potential partner/acquirer for late-stage CNS assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/remynd-nv
• Xx.com/remyndnv

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about reMYND